Convergence Investment Partners’s Enanta Pharmaceuticals ENTA Stock Holding History

Convergence Investment Partners’s Portfolio ENTA Stock Details ENTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-4,909	Closed	-$420K	–	324
2018 Q3	$420K	Sell	4,909 -6,880	-58%	-$689K	0.09%	237
2018 Q2	$1.37M	Sell	11,789 -8,479	-42%	-$846K	0.19%	153
2018 Q1	$1.64M	Buy	+20,268	New	+$1.56M	0.21%	166
2016 Q2	–	Sell	-18,148	Closed	-$533K	–	326
2016 Q1	$533K	Buy	+18,148	New	+$505K	0.06%	293
2015 Q3	–	Sell	-51,840	Closed	-$2.33M	–	361
2015 Q2	$2.33M	Buy	+51,840	New	+$2.02M	0.23%	146
2014 Q4	–	Sell	-53,130	Closed	-$2.1M	–	381
2014 Q3	$2.1M	Buy	+53,130	New	+$2.12M	0.29%	134

Other funds holding ENTA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

KAM

Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return

Convergence Investment Partners's ENTA Position: Q4 2018 in Review

Convergence Investment Partners sold out of Enanta Pharmaceuticals (ENTA) in Q4 2018, closing a stake of 4,909 shares — an estimated $420K sold.

Convergence Investment Partners first reported a position in ENTA in Q3 2014 and held it in 6 quarters. The position peaked at $2.33M in Q2 2015. 183 funds tracked by Wall St. Rank hold ENTA as of Q4 2018.

Convergence Investment Partners reported no remaining Enanta Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
Convergence Investment Partners sold 4,909 Enanta Pharmaceuticals shares in Q4 2018, an estimated $420K.
Convergence Investment Partners first reported a position in Enanta Pharmaceuticals in Q3 2014 and held it in 6 quarters.
Convergence Investment Partners's Enanta Pharmaceuticals position peaked at $2.33M in Q2 2015.
183 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q4 2018.

Based on Convergence Investment Partners's 13F filing for Q4 2018, filed 13 Feb 2019.